Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H15F2N3OS |
Molecular Weight | 311.35 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCC1=CNC(=S)N1[C@H]2COC3=C(C2)C=C(F)C=C3F
InChI
InChIKey=CWWWTTYMUOYSQA-LLVKDONJSA-N
InChI=1S/C14H15F2N3OS/c15-9-3-8-4-11(7-20-13(8)12(16)5-9)19-10(1-2-17)6-18-14(19)21/h3,5-6,11H,1-2,4,7,17H2,(H,18,21)/t11-/m1/s1
Molecular Formula | C14H15F2N3OS |
Molecular Weight | 311.35 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Etamicastat (BIA 5453) is a peripherally selective chromanyl imidazolethione-based inhibitor of dopamine beta-hydroxylase, the enzyme that catalyzes the conversion of dopamine to noradrenaline in the sympathetic nerves. Prolonged downregulation of sympathetic drive with etamicastat results in a sustained decrease in the systolic blood pressure and the diastolic blood pressure. Etamicastat was being studied by BIAL for the oral treatment of hypertension and congestive heart failure. Etamicastat development has been discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24296323
the randomized, double-blind, placebo-controlled study was conducted in male patients aged between 18 and 65 years with mild to moderate hypertension. Participants received once-daily doses of etamicastat 50, 100, or 200 mg or placebo for 10 days. Etamicastat was well tolerated and showed a pharmacokinetic profile consistent with a once-daily regimen. The antihypertensive effect of etamicastat was dose dependent up to 100 mg.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:16:16 GMT 2023
by
admin
on
Fri Dec 15 16:16:16 GMT 2023
|
Record UNII |
9X96V6DBU4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C471
Created by
admin on Fri Dec 15 16:16:16 GMT 2023 , Edited by admin on Fri Dec 15 16:16:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID00226940
Created by
admin on Fri Dec 15 16:16:16 GMT 2023 , Edited by admin on Fri Dec 15 16:16:16 GMT 2023
|
PRIMARY | |||
|
C90846
Created by
admin on Fri Dec 15 16:16:16 GMT 2023 , Edited by admin on Fri Dec 15 16:16:16 GMT 2023
|
PRIMARY | |||
|
10450387
Created by
admin on Fri Dec 15 16:16:16 GMT 2023 , Edited by admin on Fri Dec 15 16:16:16 GMT 2023
|
PRIMARY | |||
|
300000036916
Created by
admin on Fri Dec 15 16:16:16 GMT 2023 , Edited by admin on Fri Dec 15 16:16:16 GMT 2023
|
PRIMARY | |||
|
9X96V6DBU4
Created by
admin on Fri Dec 15 16:16:16 GMT 2023 , Edited by admin on Fri Dec 15 16:16:16 GMT 2023
|
PRIMARY | |||
|
C509002
Created by
admin on Fri Dec 15 16:16:16 GMT 2023 , Edited by admin on Fri Dec 15 16:16:16 GMT 2023
|
PRIMARY | |||
|
DB15288
Created by
admin on Fri Dec 15 16:16:16 GMT 2023 , Edited by admin on Fri Dec 15 16:16:16 GMT 2023
|
PRIMARY | |||
|
9101
Created by
admin on Fri Dec 15 16:16:16 GMT 2023 , Edited by admin on Fri Dec 15 16:16:16 GMT 2023
|
PRIMARY | |||
|
760173-05-5
Created by
admin on Fri Dec 15 16:16:16 GMT 2023 , Edited by admin on Fri Dec 15 16:16:16 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |